Humanigen, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 33.54 million compared to USD 32.3 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.63 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | +19,900.00% |
|
0.00% | -83.33% |
05-01 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-83.33% | 119 | |
+2.08% | 95.18B | |
-0.13% | 37.55B | |
-10.53% | 33.75B | |
+77.76% | 28.2B | |
-15.03% | 15.63B | |
-2.79% | 13.63B | |
-12.76% | 11.5B | |
+181.73% | 10.81B | |
-53.92% | 9.23B |
- Stock Market
- Equities
- HGENQ Stock
- News Humanigen, Inc.
- Humanigen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021